As of November 6, 2026, Theriva Biologics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 4, 2026 (Form 8-K, August 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Theriva Biologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Theriva Biologics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-04. Every row below is cited to the filing it comes from, and this page adds each new change as Theriva Biologics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2025-10-02 (layoff filings and notices).
Also on the record for Theriva Biologics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2025 | Stake report, Schedule 13G, by Jeffrey Matthew Gryga Irrevocable Trust | 7.7% of the class | 5%+ stakes | Source |
| October 24, 2025 | Form D, private offering | $13.11M sold | Form D page | Source |
| October 21, 2025 | Stake report, Schedule 13G/A, by Empery Asset Management, LP | 4.99% of the class | 5%+ stakes | Source |
| July 31, 2025 | Stake report, Schedule 13G, by Empery Asset Management, LP | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Theriva Biologics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Theriva Biologics, Inc. and the records around it.
Theriva Biologics, Inc. elsewhere on the record
- Form D filing Oct 2025
- Layoff notices Oct 2025
- Who owns it
Companies that share a holder
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
Watch Theriva Biologics, Inc.
Get an email when Theriva Biologics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Theriva Biologics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Theriva Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Theriva Biologics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-04 | Reported | not named in the filing | 8-K, 2026-08-04 |
New leaders reset buying decisions — get the Full Report on Theriva Biologics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Theriva Biologics, Inc., with the record behind each one.
Find candidates like senior executive at Theriva Biologics, Inc.Every change, in the filing's words
Reported
As described in the Definitive Proxy Statement, the Board of Directors has discretion to determine whether to file the Charter Amendment and may elect not to effect the amendment notwithstanding stockholder approval.
- As a result, a maximum of 6,500,000 shares of common stock may be issued under the 2020 Stock Incentive Plan, as amended.
- The results of the voting for this approved proposal are as follows: Votes For Votes Against Abstentions Broker Non-Votes 3,110,068 2,840,658 105,575 10,823,826 Proposal 4 - Approval of Amendment to Increase the Number of Authorized Shares of Common Stock.
- The stockholders approved an amendment to increase the number of authorized shares of the Company's common stock (the "Charter Amendment"), as described in the Definitive Proxy Statement.
- The results of the voting for this approved proposal are as follows: Votes For Votes Against Abstentions Broker Non-Votes 12,007,931 4,643,286 228,910 0 Proposal 5 - Approval of Issuance of Common Stock Upon Exercise of Warrants.
- The stockholders approved the issuance of shares of common stock upon the exercise of outstanding warrants, as described in the Definitive Proxy Statement.
- The results of the voting for this approved proposal are as follows: Votes For Votes Against Abstentions Broker Non-Votes 3,665,312 2,267,592 123,397 10,823,826 Proposal 6 - Approval of the Adjournment of the Annual Meeting.
- The stockholders approved a proposal to adjourn the Annual Meeting to a later date, if necessary, as described in the Definitive Proxy Statement.
Tools for this story
Each opens in a new tab, filled in for Theriva Biologics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.